B Complex Vitamins and Antioxidants

DANGER: These may be harmful

Most cancer patients and clinicians assume that more vitamins and antioxidants can only help, yet the modern data tell a very different—and often uncomfortable—story.

For the past three decades, we have quietly conducted one of the largest, real‑world experiments in supplement pharmacology in human history: mandatory folic acid fortification, widespread high‑dose B‑vitamin use, and aggressive marketing of antioxidant “immune support” to people at risk for or living with cancer. Large randomized trials and cohort studies now suggest that, depending on dose, timing, and tumor context, some of these same agents can increase cancer incidence, accelerate progression, or blunt the effects of chemotherapy and radiation.

Folate, B12, vitamin E, selenium, NAC, CoQ10, and other antioxidant supplements occupy a strange space in oncology—they are simultaneously essential for normal physiology and plausibly harmful when layered indiscriminately on top of modern cancer care. This post matters because it steps back from simplistic “pro‑” or “anti‑supplement” narratives and instead asks the harder question that actually affects patient outcomes: when do these compounds function as allies for normal tissue, and when do they become covert allies for the tumor instead? - Paul

This post provides a review for patients and clinicians alike on how to approach vitamins and antioxidants in patients with cancer. .. this happens to be an important issue.

I removed the pay-wall below to provide this important post to all readers. The pay-wall did not work exactly as I had expected.

Folic Acid

Folic acid (the synthetic form of folate) also known as Vitamin B9 is a water-soluble B vitamin found in leafy greens, legumes and cereals. In the US folate supplementation of flour is mandated. Even in well-nourished Western societies, routine supplementation of pregnant women with folate significantly reduces the risk of neural tube defects. Observational studies in the 1980 s suggested that a low-folate diet increased the risk of heart disease and colorectal cancer.(1) The enthusiasm for vitamin B supplementation led to studies to determine if it could reduce these diseases. Unfortunately, these studies proved harmful (high dose folate).

Folic acid has a dual relationship with cancer: adequate folate seems to help prevent cancer initiation, but high-dose folic acid may accelerate growth of existing pre‑cancerous or cancer cells.(2) This is one of the clearest examples in nutrition where dose, form, and timing fundamentally change biological effect.

Why folate matters in cancer biology

• Folate is essential for one‑carbon metabolism, which supports DNA synthesis, repair, and methylation; rapidly dividing cells (including tumors) depend heavily on these pathways (see figure1).(3)

• Antifolate chemotherapy (e.g., methotrexate, pemetrexed) works by blocking folate-dependent steps in nucleotide synthesis, underscoring how critical folate metabolism is for cancer cells.(4)

Potential benefits: prevention and normal tissue protection

• Low folate status is linked in many epidemiologic studies to a higher risk of colorectal adenomas and colorectal cancer; people with the highest folate levels often show about 20–40% lower risk than those with the lowest levels.(5)

• In long-term multivitamin users, ≥400 μg/day folic acid for ≥15 years was associated with up to ~75% lower colorectal cancer risk in one cohort of women.​(2)

• Adequate folate reduces DNA strand breaks and abnormal DNA methylation, mechanisms that can help prevent early carcinogenic changes in normal tissues.

• Some small intervention studies show that physiological folic acid doses can improve biomarkers of colorectal mucosal health and reverse precancerous changes, though clinical impact is modest and data are limited.(5)

Potential harms: promotion of existing neoplasia

• Experimental and translational data suggest a “U‑shaped” effect: folate deficiency may favor cancer initiation, whereas excess folic acid can promote growth of established neoplastic foci.(5)

• In colorectal models, modest folic acid supplementation (about 4–10× dietary requirement) tends to suppress tumor development in normal mucosa, but very high supplemental doses enhance growth of existing tumors or advanced lesions.(2)

Human trial data on cancer risk

• Pooled analyses of randomized trials (typical folic acid doses up to about 1 mg/day for ~5 years) generally show no major increase or decrease in overall cancer incidence within the first 5 years of treatment.

• In observational studies, lower homocysteine levels are associated with lower rates of coronary heart disease and stroke. Folic acid and vitamins B6 and B12 lower homocysteine levels. In 2006 the HOPE2 study assessed whether supplementation with these vitamins reduced the risk of major cardiovascular events in patients with vascular disease. (6) The HOPE2 found that supplementation with folate, vitamin B6 and B12 failed to reduce heart disease. However, the study demonstrated a worrisome 36% increased risk of colon cancer (not statistically significant) and a 21% increased risk of prostate cancer.

• A Norwegian trial using 0.8 mg/day folic acid plus vitamin B12 0.4mg/day in patients with cardiovascular disease reported higher overall cancer incidence and cancer mortality and all-cause mortality (HR ~1.2), raising concern that in some settings folic acid could promote cancer.(7) In this study Vitamin B(6) treatment was not associated with any significant effects. It should be noted that folate supplementation of grains and other produce is not performed in Norway.

• A large, randomized trial (Aspirin/Folate Polyp Prevention Study) raised concern that folic acid 1 mg/day increased risk of new advanced colorectal lesions and possibly multiple adenomas among patients with prior adenomas, suggesting a tumor‑promoting effect in high‑risk mucosa.(5)

• Meta-analyses and cohort studies suggest site‑specific differences:

  • Colorectal: mostly protective or neutral at physiological intakes; potential promotion at high supplemental doses, especially in people with existing neoplasia.(2)

  • Prostate: higher serum folate and folic acid supplementation have been associated in some studies with increased prostate cancer risk.​(5)

  • Breast and others: evidence is mixed and often suggests a U‑shaped relationship, with risk lowest at intermediate folate levels.(5)

• High folate can:

  • Increase DNA methylation of tumor suppressor genes

  • Promote oncogene silencing/activation patterns favorable to cancer survival

Use after a cancer diagnosis

• Many cancer patients use supplements containing folic acid; in colorectal cancer cohorts, post‑diagnosis folic acid–containing supplement use is common and often higher than before diagnosis.(8)

• Preclinical and mechanistic work indicates that high folate availability can support cancer cell proliferation by fueling nucleotide synthesis and one‑carbon metabolism, which may theoretically worsen prognosis.(9)

• For colorectal cancer patients treated with 5‑fluorouracil (5‑FU), low folate status can increase treatment sensitivity by downregulating thymidylate synthase, whereas continued folic acid supplement use could reduce 5‑FU efficacy. (10)

• Because of these uncertainties, several expert and research groups highlight the possibility that high folic acid intake may speed tumor growth or interfere with therapy in some cancers and call for careful evaluation of post‑diagnosis supplementation.(5, 8)

Practical implications

• For general prevention: maintaining adequate dietary folate (from foods or standard multivitamins around 400 μg folic acid/day) appears reasonable and may lower risk of some cancers, particularly colorectal, without clear evidence of short‑term harm.

• For high‑dose supplements (≥1 mg/day) or fortified products taken in addition to a multivitamin, long‑term safety regarding cancer promotion is uncertain, especially in people with existing adenomas or prior cancers.

• For people with a current or past cancer diagnosis, high‑dose supplements (≥1 mg/day) should be avoided.

Vitamin B12

Vitamin B12 is essential for cell function, but its role in cancer is complex: deficiency is common in many cancer patients and should be treated, while long‑term high‑dose supplementation without a clear indication is not recommended because of concerning epidemiologic signals of worse outcome.(11)

What vitamin B12 does

• Vitamin B12 is a cofactor in one‑carbon metabolism, needed for DNA synthesis, methylation, and mitochondrial energy pathways, all of which are relevant to tumor biology.(11)

• Deficiency can cause anemia, neuropathy, cognitive changes, and glossitis, which can significantly worsen quality of life in people with cancer.

B12 deficiency in cancer patients

• Cancer patients frequently develop B12 deficiency due to gastrectomy, ileal resection, gastric or small‐bowel tumors, metformin, proton‑pump inhibitors, poor intake, or malabsorption.(11)

• After gastrectomy for gastric cancer, functional deficiency detected by methylmalonic acid and homocysteine is more common than suggested by serum B12 alone, highlighting the need for better markers in this group.(12)

B12 levels and cancer risk/prognosis

• Observational studies show that elevated plasma B12 is associated with higher overall cancer incidence and with worse outcome. (13)

• A meta‑analysis of general populations found a linear association between higher serum B12 and all‑cause mortality. (14)

• In the Cooperative Group Clinical Trial (SWOG S0221) patients with breast cancer randomly assigned to an intergroup metronomic trial of cyclophosphamide, doxorubicin, and paclitaxel were queried on their use of supplements at registration and during treatment. (15) In this study the use of vitamin B12 both before and during chemotherapy was significantly associated with poorer disease-free survival (HR, 1.83; 95% CI, 1.15 to 2.92; P<0.01) and overall survival (HR, 2.04; 95% CI, 1.22 to 3.40; P<0.01).

Practical takeaways for clinical use

• Long‑term high‑dose B12 supplementation without a clear indication—especially in smokers or in combination with high‑dose folate—should be avoided because of the possible links to an increased risk of lung and other cancers.

• It is appropriate to screen cancer patients with anemia, neuropathy, prior gastric/ileal surgery, or malabsorption risk for B12 deficiency, ideally using methylmalonic acid and homocysteine when available.

• When true deficiency is present, B12 should be replaced; there is no convincing evidence that correcting deficiency promotes tumor growth, and untreated deficiency can worsen neurologic and hematologic complications

• Long‑term high‑dose B12 supplementation especially in combination with high‑dose folate should be avoided in patients with cancer as this appears to be associated with poorer disease free and overall survival.

Antioxidants

Antioxidants play a complex role in cancer: getting them from food is generally considered safe and may modestly reduce risk, but high‑dose supplements can sometimes increase cancer risk or interfere with treatment, so they are usually not recommended during chemotherapy or radiation. (16)

What antioxidants do

Antioxidants (like vitamins A, C, E, beta‑carotene, selenium, and others) neutralize reactive oxygen species (ROS), which can otherwise damage DNA, proteins, and cell membranes. This DNA damage can contribute to the development of cancer, so in theory antioxidants might help prevent some cancers by limiting oxidative stress. (17)

Antioxidants and cancer prevention

Population and clinical studies show that antioxidant‑rich diets (fruits, vegetables, whole grains, nuts) are associated with lower risk of several cancers, but this effect is modest and part of an overall healthy lifestyle. In contrast, large, randomized trials of high‑dose antioxidant supplements like beta‑carotene, vitamin E, and selenium have often shown no benefit and in some cases increased risks of lung or prostate cancer, especially in smokers and older men.(16)

Antioxidants and cancer progression

Cancer cells also use antioxidants to protect themselves from ROS, which they generate at high levels because of rapid growth and altered metabolism. To survive, tumors up-regulate antioxidant defenses (glutathione, Nrf2, thioredoxin systems). In several mouse models of lung cancer and melanoma, supplements like N‑acetylcysteine (NAC) and vitamin E lowered ROS in tumors, reduced activation of tumor‑suppressor pathways (such as p53), and accelerated tumor growth and metastasis.(18)

In an experimental model, Wang et al demonstrated that vitamin C, vitamin E and n-acetylcysteine (NAC) increased tumor angiogenesis by BACH1 mechanism (redox-sensitive transcription factor BTB and CNC homology 1). (19)

In the Cooperative Group Clinical Trial (cited above) the use of any antioxidant supplement (vitamins A, C, and E; carotenoids; coenzyme Q10) both before and during treatment was associated with an increased hazard of recurrence (HR 1.41; 95% CI, 0.98 to 2.04; P = .06). (15)

In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) vitamin E was associated with a significant increased risk of prostate cancer (HR 1.17, 99% CI 1.004-1.36, p=.008).

Antioxidants during chemotherapy and radiation

Many standard chemotherapies and all external‑beam radiation treatments work in part by generating ROS to damage cancer cell DNA. High‑dose antioxidant supplements could theoretically shield cancer cells from this ROS, potentially making treatment less effective or altering drug pharmacology.

• Reviews and expert groups advise against taking antioxidant supplements during chemotherapy or radiotherapy because clinical trials have not shown clear benefit and some suggest possible worse outcomes.(20)

• A prospective breast cancer study found that patients taking antioxidant supplements around chemotherapy had higher risks of recurrence and death.(21)

Conclusions:

• Favor dietary antioxidants: eat plenty of vegetables, nuts, and legumes rather than relying on pills.

• Avoid self‑prescribing antioxidant supplements (vitamins A, C, E, beta‑carotene, selenium, NAC, high‑dose herbal “antioxidant” blends) if you have cancer, especially during chemotherapy or radiation.

Oral versus IV vitamin C

Oral vitamin C

Acts as a classic antioxidant:

• Scavenges ROS

• Regenerates vitamin E

• Supports collagen synthesis and immune function

• Reduces inflammation and endothelial dysfunction

In cancer:

• No reliable direct tumoricidal effect

• No clinical benefit however may promote tumor growth

Practical oncology guidance

Reasonable approach for most cancer patients:

• ✔️ 200–500 mg/day if dietary intake is inadequate

• ✔️ Up to 1 g/day short-term for deficiency or acute stress

• ❌ Avoid ≥2 g/day chronically

• ❌ Avoid during active chemo-RT unless there is a clear indication

• ❌ Avoid with kidney disease, iron overload, or prior oxalate stones

IV vitamin C (high dose)

At millimolar plasma levels:

Reduces Fe³⁺ → Fe²⁺

• Generates extracellular hydrogen peroxide (H₂O₂)

• Cancer cells (low catalase, impaired redox buffering) accumulate lethal oxidative damage

• Normal cells detoxify H₂O₂ efficiently

• Cytotoxic to cancer

Table 1. Pharmacokinetics of vitamin C.

Selenium

Selenium is an essential trace mineral involved in antioxidant defense and immune function, but current evidence does not support using selenium supplements as a stand‑alone treatment for prevention or treatment of cancer, and benefits as an add‑on therapy are limited and inconsistent.

A Cochrane review concluded “Well‐designed and well‐conducted RCTs have shown no beneficial effect of selenium supplements in reducing cancer risk (high certainty of evidence). Some RCTs have raised concerns by reporting a higher incidence of high‐grade prostate cancer and type 2 diabetes in participants with selenium supplementation. No clear evidence of an influence of baseline participant selenium status on outcomes has emerged in these studies.”(22)

Emerging population data suggest a U‑shaped relationship, in which cancer risk is lowest at moderate selenium intake and increases at both low and high intakes.(23) Because of this, unsupervised high‑dose supplementation, especially in people who already have adequate selenium from diet, is discouraged.

In a follow up of the SELECT study an analysis found that men who already had high baseline selenium status and then took selenium supplements had almost double the risk of high‑grade prostate cancer compared with similar men on placebo.(24) Men with low baseline selenium who took vitamin E had about double the risk of high‑grade prostate cancer compared with low‑selenium men on placebo, suggesting an adverse interaction between high‑dose supplements and existing selenium status.(24)

Bottom line

• Vitamin E 400 IU/day increased prostate cancer risk; selenium 200 micrograms/day did not prevent prostate cancer and may be harmful in men with high baseline selenium.

• Major cancer organizations now advise against using high‑dose selenium or vitamin E supplements for prostate cancer prevention based on SELECT.(25, 26)

Recommended intake of selenium for cancer patients

For most adults with cancer, the recommended daily selenium intake is the same as for the general population (about 55 micrograms per day from food and any supplements combined), unless the patient has a documented deficiency.

U.S. and international guidelines set the Recommended Dietary Allowance for adults at about 55 micrograms per day. This amount is usually reached through a normal diet including meat, seafood, eggs, and grains, so most patients do not need extra selenium

In selenium deficient patients, newer risk analyses suggest long‑term intakes may be safest in a narrower band, roughly around 110–125 micrograms per day, with risk increasing again at higher intakes, which reinforces avoiding high‑dose, long‑term supplements. (23, 27)

N-acetyl Cysteine (NAC)

What NAC is and how it might affect cancer

• NAC is an oral supplement and prescription drug that replenishes glutathione, a major intracellular antioxidant, and is used for acetaminophen overdose and some lung diseases.

• NAC is a precursor to glutathione (GSH), the cell’s dominant intracellular antioxidant. Through this, it:

  • Scavenges reactive oxygen species (ROS)

  • Restores redox balance

  • Modulates NF-κB, MAPK, and p53 signaling

  • Influences ferroptosis and apoptosis

· Alters immune cell and stromal redox tone

• In lab and animal models, NAC shows antimutagenic, anticarcinogenic, and anti‑invasive effects, including reducing oxidative DNA damage and limiting tumor invasion.​(28, 29)

• However, NAC can also protect cancer cells from oxidative damage; in some mouse models, antioxidants like NAC accelerated tumor growth and metastasis by lowering reactive oxygen species that normally restrain malignant cells. (30, 31)

Evidence for cancer prevention

• A large 2025 Taiwanese cohort of patients with COPD (over 130,000 individuals) found that long‑term NAC use was associated with lower overall cancer risk, with an adjusted hazard ratio about 0.69 versus non‑users and a clear dose–response (higher cumulative dose → lower risk).(29)

• Importantly, this was an observational study in a high‑risk respiratory population, so it cannot prove causation, and confounding (health behaviors, other medications) is possible.

Evidence in people already diagnosed with cancer

• There is no definitive clinical trial showing that NAC improves overall survival, progression‑free survival, or cure rates when added to standard cancer therapy.

• Work in mouse and cell models has shown that antioxidants such as NAC and vitamin E can reduce ROS and DNA damage in cancer cells, but in some settings this reduction eliminated expression of endogenous tumor‑suppressive pathways and increased tumor growth and invasiveness.(30, 31)

Summary

• If you are generally healthy and thinking about NAC purely to prevent cancer, current data are not strong enough to justify it for that purpose alone, focusing on established risk‑reduction strategies (not smoking, weight management, ROOT protocol) has far more proven benefit.

• Antioxidant treatment in patients with cancer has been demonstrated to cause tumor progression and worsen outcome; therefore, this supplement should be avoided in patients with cancer.

Coenzyme Q (CoQ)

Evidence does not support coenzyme Q10 (CoQ10) as an effective treatment to shrink or cure cancer. CoQ10 (coenzyme Q10) is generally considered low‑toxicity, but in people with cancer the main potential harm is that it may interfere with some treatments, especially radiation and certain chemotherapies, rather than clearly making tumors grow on their own. However, mitochondrial ubiquinol oxidation has been demonstrated to be necessary for tumor growth.(32)

What CoQ10 is and why it’s considered

CoQ10 is a vitamin‑like compound involved in mitochondrial energy production and acting as an antioxidant in cells.(33)​ Because oxidative stress and mitochondrial dysfunction are implicated in cancer biology and chemotherapy toxicity, researchers have explored CoQ10 for possible protective or adjunct roles rather than as a stand‑alone cancer drug.

In‑vitro data suggest CoQ10 might protect cancer cells from apoptosis or blunt the effect of drugs that kill cells via oxidative damage, raising theoretical concerns that high‑dose antioxidant use could interfere with certain chemotherapies or targeted agents.

Human Data

CoQ10 and other antioxidants including Vitamin A and Vitamin E have been demonstrated to be associated with an increased risk of developing prostate cancer. (34)

In a cohort of breast cancer patients, use of antioxidant supplements (including CoQ10) before and during chemotherapy was associated with a higher hazard of recurrence.(35)

Trials in breast‑cancer patients testing CoQ10 for treatment‑related fatigue did not find meaningful improvements in fatigue or overall quality of life compared with placebo.

Summary

Despite a benign safety profile, routine CoQ10 use in cancer patients is not recommended because clear clinical benefit is lacking and potential interference with treatment remains possible.

References

1. Fung J. The Cancer Code. New York, NY: Harper Collins; 2020.

2. Kim YI. Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2220–5.

3. Rosenzweig A, Blenis J, Gomes AP. Beyond the Warburg Effect: How Do Cancer Cells Regulate One-Carbon Metabolism? Front Cell Dev Biol. 2018;6:90.

4. Shuvalov O, Petukhov A, Daks A, Fedorova O, Vasileva E, Barlev NA. One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy. Oncotarget. 2017;8(14):23955–77.

5. Pieroth R, Paver S, Day S, Lammersfeld C. Folate and Its Impact on Cancer Risk. Curr Nutr Rep. 2018;7(3):70–84.

6. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–77.

7. Ebbing M, Bønaa KH, Nygård O, Arnesen E, Ueland PM, Nordrehaug JE, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. Jama. 2009;302(19):2119–26.

8. Holmes RS, Zheng Y, Baron JA, Li L, McKeown-Eyssen G, Newcomb PA, et al. Use of folic acid-containing supplements after a diagnosis of colorectal cancer in the Colon Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2023–34.

9. Cao X, Guo Y, Guo Z, Liu Y, Dou Y, Xue L. One-carbon metabolism in cancer: moonlighting functions of metabolic enzymes and anti-tumor therapy. Cancer Metastasis Rev. 2025;44(4):91.

10. Dekhne AS, Hou Z, Gangjee A, Matherly LH. Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer. Mol Cancer Ther. 2020;19(11):2245–55.

11. Osmola M, Tyszka M, Jirka A, Ciepiela O, Kapała A, Lenti MV, et al. Vitamin B12 in Cancer Patients: Clinical Insights into Deficiency, Excess, Diagnosis, and Management. Nutrients. 2025;17(20).

12. Vashi P, Edwin P, Popiel B, Lammersfeld C, Gupta D. Methylmalonic Acid and Homocysteine as Indicators of Vitamin B-12 Deficiency in Cancer. PLoS One. 2016;11(1):e0147843.

13. Obeid R. High Plasma Vitamin B12 and Cancer in Human Studies: A Scoping Review to Judge Causality and Alternative Explanations. Nutrients. 2022;14(21).

14. Liu K, Yang Z, Lu X, Zheng B, Wu S, Kang J, et al. The origin of vitamin B12 levels and risk of all-cause, cardiovascular and cancer specific mortality: A systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2024;117:105230.

15. Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, et al. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin. Oncol. 2020;38(8):804–14.

16. Schmidt S, Qiao X, Bergö MO. Effects of antioxidants on cancer progression. EMBO Mol Med. 2025;17(8):1896–901.

17. Fagbohun OF, Gillies CR, Murphy KPJ, Rupasinghe HPV. Role of Antioxidant Vitamins and Other Micronutrients on Regulations of Specific Genes and Signaling Pathways in the Prevention and Treatment of Cancer. Int J Mol Sci. 2023;24(7).

18. Hecht F, Zocchi M, Alimohammadi F, Harris IS. Regulation of antioxidants in cancer. Mol Cell. 2024;84(1):23–33.

19. Zhang W, Quan Y, Ma X, Zeng L, Li J, Chen S, et al. Synergistic effect of glutathione and IgG4 in immune evasion and the implication for cancer immunotherapy. Redox Biol. 2023;60:102608.

20. D’Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin. 2005;55(5):319–21.

21. Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, et al. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2020;38(8):804–14.

22. Vinceti M, Filippini T, Del Giovane C, Dennert G, Zwahlen M, Brinkman M, et al. Selenium for preventing cancer. Cochrane Database Syst Rev. 2018;1(1):Cd005195.

23. Le NT, Pham YT, Le CT, Le LT, Le TD, Dao HV, et al. A U-shaped association between selenium intake and cancer risk. Sci Rep. 2024;14(1):21378.

24. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106(3):djt456.

25. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39–51.

26. Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.

27. Grober U, Kisters K. Selenium in Oncological Intervention. British Journal of Cancer Research. 2019:304–7.

28. Delneste Y, Jeannin P, Potier L, Romero P, Bonnefoy JY. N-acetyl-L-cysteine exhibits antitumoral activity by increasing tumor necrosis factor alpha-dependent T-cell cytotoxicity. Blood. 1997;90(3):1124–32.

29. Yang CC, Chen WM, Shia BC, Wu SY. Impact of long-term N-acetylcysteine use on cancer risk. Am J Cancer Res. 2025;15(2):618–30.

30. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 2014;6(221):221ra15.

31. Zou ZV, Le Gal K, El Zowalaty AE, Pehlivanoglu LE, Garellick V, Gul N, et al. Antioxidants Promote Intestinal Tumor Progression in Mice. Antioxidants (Basel). 2021;10(2).

32. Martínez-Reyes I, Cardona LR, Kong H, Vasan K, McElroy GS, Werner M, et al. Mitochondrial ubiquinol oxidation is necessary for tumour growth. Nature. 2020;585(7824):288–92.

33. Garrido-Maraver J, Cordero MD, Oropesa-Avila M, Vega AF, de la Mata M, Pavon AD, et al. Clinical applications of coenzyme Q10. Front Biosci (Landmark Ed). 2014;19(4):619–33.

34. Loh WQ, Yin X, Kishida R, Chia SE, Ong CN, Seow WJ. Association between Vitamin A and E Forms and Prostate Cancer Risk in the Singapore Prostate Cancer Study. Nutrients. 2023;15(12).

35. Woldeselassie M, Tamene A. Therapeutic controversies over use of antioxidant supplements during cancer treatment: a scoping review. Front Nutr. 2024;11:1480780.